We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

TEVA
Teva Pharmaceutical Industries Limited
NYSE
People also watch : MYL NVS AMGN GILD ABT
53.50 -1.29 (-2.35%)

After hours: 53.570.07 (0.13%) as of 5:45 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close 54.79
Open 54.79
Bid 53.61 x 100
Ask 53.74 x 100
52wk Range 48.01 - 71.68
Day's Range 53.33 - 54.83
Volume 4,927,624
Avg Vol (3m) 6,179,404
As of 4:00 PM EDT. Market closed.
  • Investopedia 2 days ago

    Pfizer Exits Brazil: Teva Is Suitor (PFE, TEVA)

    Pfizer is planning to exit the Brazilian market as it puts its generic drug joint venture stake up for sale. Teva and Mylan are possible bidders for the asset.

  • TheStreet.com 3 days ago

    Teva (TEVA) Stock Up, Allergen Deal Receives Clearance

    Teva Pharmaceuticals (TEVA) stock is rising in early morning trading today after the company won antitrust approval to purchase Allergan's (AGN) generics business.

  • Market Realist 3 days ago

    Teva Pharmaceutical Finance Issued the Most High-Grade Bonds

    US corporates dominated the primary market for high-grade bonds in the week ending July 22—making up 52.8% or $16.0 billion of all the issues.

  • Reuters 3 days ago

    Teva, Allergan win U.S. antitrust approval for generics deal

    Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest 79 generic drugs to rival firms, the Federal Trade Commission said ...

  • Associated Press 3 days ago

    Teva expect to close $40.5B Allergan generic deal next week

    Israeli drugmaker Teva, the largest generic drug company in the world, said Wednesday it expects to complete its $40.5 billion purchase of the generic drug business of competitor Allergan next week after ...

  • The Wall Street Journal 4 days ago

    [$$] Teva, Allergan Get FTC Approval for Generics Purchase

    Teva Pharmaceutical Industries Ltd. on Wednesday won regulatory approval from the Federal Trade Commission for its acquisition of Allergan PLC’s generics business, conditioned upon Teva’s divestiture of ...

  • American City Business Journals 4 days ago

    FTC approves Teva's $40.5B deal for Allergan's generics business

    The Federal Trade Commission on Wednesday gave its approval to Teva Pharmaceutical Industries Ltd.’s proposed $40.5B acquisition of Allergan’s generics business. The approval was granted after Teva agreed to divest more than 75 generic drugs to rival businesses — marking the largest drug divestiture order in an FTC pharmaceutical merger case. “Millions of Americans rely daily on generic drugs to treat a wide range of illnesses,” said Debbie Feinstein, director of the FTC’s Bureau of Competition.

  • Bloomberg 4 days ago

    Teva Wins U.S. Nod for Actavis After Divestiture of 79 Drugs

    The U.S. Federal Trade Commission approved Teva Pharmaceutical Industries Ltd.’s $40.5 billion purchase of Allergan Plc’s generic drug-making unit after the companies agreed to the biggest divestiture ...

  • Bloomberg 4 days ago

    Teva Wins U.S. Approval to Buy Actavis After Selling Generics

    The U.S. Federal Trade Commission approved Teva Pharmaceutical Industries Ltd.’s $40.5 billion purchase of Allergan Plc’s generic drug-making unit after the companies agreed to divest certain drugs to ...

  • Teva Said Close to Closing $40.5 Billion Allergan Deal
    Bloomberg Video 3 days ago

    Teva Said Close to Closing $40.5 Billion Allergan Deal

    July 28 -- The U.S. Federal Trade Commission is close to signing off on Teva Pharmaceutical's deal to buy Allergan Plc's generics unit for $40.5 billion according to people familiar with the matter. Bloomberg's Elliot Gotkine reports on "Bloomberg Markets Middle East."